Loading
institutionsInstitution
Mays Cancer Center at UT Health San Antonio
Mays Cancer Center in San Antonio, NCI-designated since 1991, hosts the San Antonio Breast Cancer Symposium and descends from the CTRC phase 1 institute where Daniel Von Hoff ran early trials of gemcitabine and nab-paclitaxel; it serves South Texas's predominantly Latino population.
Also called: CTRCCancer Therapy & Research Center
Overview
Mays Cancer Center descends from the Cancer Therapy & Research Center, NCI-designated since 1991, whose Institute for Drug Development under Daniel Von Hoff conducted early trials of gemcitabine and nab-paclitaxel among other agents. UT Health San Antonio founded the San Antonio Breast Cancer Symposium in 1977, now the world's largest breast cancer meeting, co-hosted with the AACR and Baylor's Smith Breast Center. The centre serves South Texas's predominantly Latino population, with Amelie Ramirez's Salud America! programme addressing Latino cancer disparities, and hosts the Greehey Children's Cancer Research Institute. It is an MD Anderson affiliate and has strengths in myeloproliferative neoplasms and breast oncology.
Location
San Antonio, TX, US
Type
cancer center · UT Health San Antonio
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
clinical
OnCo score
#120 · 36 points (0 Newsweek + 8 NCI + 28 from 14 linked objects) · ranking
- San Antonio Breast Cancer Symposium
- Phase 1 drug development (IDD heritage)
- Latino cancer disparities
- Paediatric research (Greehey CCRI)
Similar pages
- CollectionLiving Beyond Breast Cancer
Shares San Antonio Breast Cancer Symposium, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionO'Neal Comprehensive Cancer Center at UAB
Shares NCI-Designated Cancer Centers, Trials do not represent the people who get cancer, National Cancer Institute (NIH), Pancreatic ductal adenocarcinoma.
- InstitutionBarbara Ann Karmanos Cancer Institute
Shares NCI-Designated Cancer Centers, Trials do not represent the people who get cancer, National Cancer Institute (NIH), HR-positive / HER2-negative breast cancer.
- IdeaFund investigators from under-represented communities and community sites to lead trials
Shares American Association for Cancer Research (AACR), Trials do not represent the people who get cancer, National Cancer Institute (NIH).
- InstitutionUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, Trials do not represent the people who get cancer, National Cancer Institute (NIH), HR-positive / HER2-negative breast cancer.
- InstitutionSalk Institute Cancer Center
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma.
- InstitutionUC Davis Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, Trials do not represent the people who get cancer, National Cancer Institute (NIH).
- InstitutionVCU Massey Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, Trials do not represent the people who get cancer, National Cancer Institute (NIH).
cancers
fronts
drugs
ApprovedNucleoside analogue (deoxycytidine)
Gemcitabine · Gemzar / Infugem
ApprovedSmall-molecule JAK1/JAK2 inhibitor
Ruxolitinib · Jakafi / Jakavi